Class Action Sued Ardelyx Over Drug Allegations

ATLANTA, Sept. 18, 2026 /CourierPR/ -- A shareholder class action lawsuit has been filed against Ardelyx, Inc. (NASDAQ: ARDX) over alleged false and misleading statements regarding its two core drugs, IBSRELA and XPHOZAH. The lawsuit, brought by Holzer & Holzer, LLC, alleges that the company made material misrepresentations about its drugs, potentially harming investors.

Holzer & Holzer, a top-rated securities litigation law firm, is encouraging investors who purchased Ardelyx shares between January 13, 2025, and August 6, 2026, and experienced a loss on their investment to contact the firm.

The deadline for investors to ask the court to be appointed as lead plaintiff in the case is November 16, 2026. Holzer & Holzer, LLC, which has been recognized as an ISS top-rated securities litigation law firm for the past five years, has a history of recovering hundreds of millions of dollars for shareholders. Since its founding in 2000, the firm has played a critical role in numerous high-profile cases, advocating for the rights of investors and holding companies accountable for fraudulent practices.

Holzer & Holzer's dedication to vigorous representation of shareholders and investors is evident in its extensive track record. The firm's attorneys have been at the forefront of some of the most significant corporate misconduct cases, ensuring that victims of fraud are not left without recourse. Investors who believe they may have a case are encouraged to contact the firm directly for more information.

For those interested in learning more about the lawsuit or seeking legal advice, Holzer & Holzer, LLC can be reached by toll-free telephone at (888) 508-6832 or by visiting their website at www.holzerlaw.com/case/ardelyx.